申请人:Ayesa Susana
公开号:US20130172232A1
公开(公告)日:2013-07-04
Compounds of the formula I
wherein
R
2a
and R
2b
are independently H, halo, C
1
-C
4
alkyl, C
1
-C
4
haloalkyl or C
1
-C
4
alkoxy, or R
2a
and R
2b
together with the carbon atom to which they are attached form a C
3
-C
6
cycloalkyl;
R
3
is a C
5
-C
10
alkyl, optionally substituted with 1-3 substituents independently selected from halo, C
1
-C
4
haloalkyl, C
1
-C
4
alkoxy, C
1
-C
4
haloalkoxy; or
R
3
is a C
2
-C
4
alkyl chain with at least 2 chloro or 3 fluoro substituents; or
R
3
is C
3
-C
7
cycloalkylmethyl, optionally substituted with 1-3 substituents independently selected from C
1
-C
4
alkyl, halo, C
1
-C
4
haloalkyl, C
1
-C
4
alkoxy, C
1
-C
4
haloalkoxy;
R
4
is C
1
-C
6
alkyl, C
1
-C
6
haloalkyl, C
1
-C
6
alkoxy, C
1
-C
6
haloalkoxy, C
1
-C
6
alkylamino, C
1
-C
6
dialkylamino or;
R
4
is Het or Carbocyclyl, either of which is optionally substituted with 1-3 substituents R
4
is Het, carbocyclyl, C
1
-C
6
alkyl, C
1
-C
6
haloalkyl, C
1
-C
6
alkoxy or C
1
-C
6
haloalkoxy;
n is 1, 2 or 3;
for the use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.
化合物的公式为I,其中R2a和R2b独立地为H、卤素、C1-C4烷基、C1-C4卤代烷基或C1-C4烷氧基,或者R2a和R2b与它们连接的碳原子一起形成C3-C6环烷基;R3是C5-C10烷基,可选地被1-3个卤素、C1-C4卤代烷基、C1-C4烷氧基或C1-C4卤代烷氧基独立地取代;或者R3是具有至少2个氯或3个氟取代基的C2-C4烷基链;或者R3是C3-C7环烷基甲基,可选地被1-3个C1-C4烷基、卤素、C1-C4卤代烷基、C1-C4烷氧基或C1-C4卤代烷氧基独立地取代;R4是C1-C6烷基、C1-C6卤代烷基、C1-C6烷氧基、C1-C6卤代烷氧基、C1-C6烷基氨基、C1-C6二烷基氨基或者R4是Het或Carbocyclyl,它们中的任意一个可选地被1-3个取代基取代,其中R4是Het、carbocyclyl、C1-C6烷基、C1-C6卤代烷基、C1-C6烷氧基或C1-C6卤代烷氧基;n为1、2或3;用于预防或治疗由于cathepsin S不适当的表达或激活而表现出的障碍。